Get the Stockscreener App
6.765
1.20%
0.105
Actuate Therapeutics Inc stock is traded at $6.765, with a volume of 793.
It is up +1.20% in the last 24 hours and down -3.44% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$6.66
Open:
$6.67
24h Volume:
793
Relative Volume:
0.01
Market Cap:
$162.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.29%
1M Performance:
-3.44%
6M Performance:
-35.99%
1Y Performance:
-13.92%
1-Day Range:
$6.67
$7.01
1-Week Range:
$6.295
$7.2872
52-Week Range:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
7.01 | 154.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.23 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.90 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.39 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.24 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Real time scanner hits for Actuate Therapeutics Inc. explainedRate Cut & High Conviction Buy Zone Alerts - newser.com
Why Actuate Therapeutics Inc. stock could benefit from AI revolution2025 Short Interest & High Accuracy Trade Signal Alerts - newser.com
What’s next for Actuate Therapeutics Inc. stock priceEarnings Growth Report & Entry Point Strategy Guides - newser.com
Using R and stats models for Actuate Therapeutics Inc. forecastingEarnings Miss & Weekly Watchlist of Top Performers - newser.com
What makes Actuate Therapeutics Inc. stock attractive to growth fundsGlobal Markets & Free High Return Stock Watch Alerts - newser.com
What indicators show strength in Actuate Therapeutics Inc.July 2025 Setups & Verified Momentum Stock Watchlist - newser.com
Published on: 2025-11-01 09:18:34 - newser.com
Advanced analytics toolkit walkthrough for Actuate Therapeutics Inc.Earnings Summary Report & Weekly Stock Performance Updates - newser.com
Is it time to cut losses on Actuate Therapeutics Inc.2025 Market Trends & Detailed Earnings Play Strategies - newser.com
How Actuate Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Weekly Recap & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-10-31 03:58:11 - newser.com
Is Actuate Therapeutics Inc. building a consolidation baseExit Point & AI Driven Stock Movement Reports - newser.com
How Actuate Therapeutics Inc. stock benefits from tech adoptionEarnings Recap Summary & Daily Stock Trend Watchlist - newser.com
Is Actuate Therapeutics Inc. stock gaining market shareStop Loss & Weekly Watchlist for Hot Stocks - Fundação Cultural do Pará
Actuate Therapeutics shares sink on pricing of $15M public offering of common stock - MSN
Is Actuate Therapeutics Inc. stock near bottom after decline2025 Major Catalysts & Stock Portfolio Risk Control - fcp.pa.gov.br
EMA gives OMPD to Actuate’s pancreatic cancer therapy - MSN
Published on: 2025-10-27 18:21:51 - newser.com
Strategies to average down on Actuate Therapeutics Inc.Bond Market & Real-Time Stock Price Movement Reports - newser.com
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):